Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist—protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol

INTRODUCTION: Antipsychotic medication is widely associated with dysmetabolism including obesity and type 2 diabetes, cardiovascular-related diseases and early death. Obesity is considered the single most important risk factor for cardiovascular morbidity and mortality. Interventions against antipsy...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishøy, Pelle L, Knop, Filip K, Broberg, Brian V, Baandrup, Lone, Fagerlund, Birgitte, Jørgensen, Niklas R, Andersen, Ulrik B, Rostrup, Egill, Glenthøj, Birte Y, Ebdrup, Bjørn H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2014
Materias:
Mental Health
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3902332/
https://www.ncbi.nlm.nih.gov/pubmed/24401727
http://dx.doi.org/10.1136/bmjopen-2013-004158

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3902332/
https://www.ncbi.nlm.nih.gov/pubmed/24401727
http://dx.doi.org/10.1136/bmjopen-2013-004158

Ejemplares similares